denverhealthmedicalplan.org
Dec 16, 2024, 19:28
Akhil Santhosh: The key differences between “KEYNOTE 522” and “CAMRELIEF”
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“With the arrival of camrelizumab in the NACT space for TNBS. Let’s look at the key differences between ‘KEYNOTE 522’ and ‘CAMRELIEF’
- Camrelizumab trial included more percentage of higher-risk patients (the trial included n3 disease also).
- Because of that. Path Crs were a bit lower with camreli compared to pembrolizumab (56.8% vs 64.8%).
But the path cr delta between IO and placebo arm was similar in the 3 trials (around 12%) - NACT arm in camrelizumab study used nab pacli instead of conventional pacli.
- Also weekly nab pacli plus carbo auc 5 was completed in 16 weeks compared to 12 weeks in keynote 522
Dose-dense AC was used in Camrelief compared to 3 weekly in keynote 522. - Reactive capillary endothelial proliferation is a unique side effect associated with camrelizumab, which occurred in 87.7% of patients. Previous HCC studies have shown that patients who develop this have better outcomes. The same with Camrelief is yet to be seen.
- Similar to keynote 522, path cr with addition of IO is not dependent on pdl1 expression.
This is unlike the metastatic setting (keynote 355 and impassion 130) where higher cps scores correlated with better survival.”
More posts featuring Akhil Santhosh.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 16, 2024, 19:28
Dec 16, 2024, 19:16
Dec 16, 2024, 19:07
Dec 16, 2024, 19:00
Dec 16, 2024, 18:45